聚乙二醇化干扰素治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎患者乙型肝炎病毒表面抗原消失的相关因素

Predictive factors of hepatitis B surface antigen loss in hepatitis B e antigen-positive chronic hepatitis B patients during pegylated interferon treatment

目的探讨聚乙二醇化干扰素（PEGqFNa～2a）治疗HBeAg阳性慢性乙型肝炎（CHB）患者过程中预测HBsAg消失的相关因素。方法对72例HBeAg阳性CHB患者，应用PEG—IFNα-2a180p．g，每周1次，共48周。每3个月检测ALT、AST及HBVDNA、HBeAg和H13sAg定量，对48周治疗结束时HBsAg消失与基线、12周、24周的HBVDNA、HBeAg和HBsAg定量的相关关系进行分析。计数资料行Fisher精确检验及受试者工作特征（ROC）曲线分析。结果65例HBeAg阳性CHB患者完成本研究，其中7例HBsAg消失。48周时HBsAg的消失与治疗12周时HBeAg水平有关（Fisher确切概率法，P=0．023），与治疗24周时HBeAg水平高度相关（Fisher确切概率法，p=0．004），与12周或24周时HBsAg-250IU／mL相关（Fisher确切概率法，P=0．001，P=0．002）。与12周时HBVDNA阴转相关（Fisher确切概率法，P=0．039），而与24周时HBVDNA是否阴转无关（Fisher确切概率法，P=0．130）。经ROC曲线分析显示，12周、24周HBsAg及24周HBeAg曲线下面积（AUC）分别为0．8584（P=0．0021）、0．9606（P=0．001）及0．8350（P=0．040）。结论联合应用24周HBeAg和HBsAg定量水平可能是预测48周疗程结束时是否发生HBsAg消失的有效指标。

Objective To identify the predictive factors antigen （HBsAg） loss in hepatitis g e antigen （HBeAg）-positive treated with pegylated interferon （PEG-IFNα-2α）. Methods associated with hepatitis B surface chronic hepatitis B （CHB） patients Seventy-two HBeAg positive CHB patients were treated with PEG-IFNα-2α 180 μg weekly for 48 weeks. The serum levels of alanine aminotransferase （ALT）, aspartate aminotransferase （AST） and hepatitis B virus （HBV） DNA, HBeAg, and HBsAg were quantitatively detected every 3 months. The relationship between HBV DNA, HBeAg, and HBsAg levels at baseline, week 12, 24 of treatment and HBsAg loss was analyzed. The data were statistically assessed by Fisher＇s exact test, and receiver operating characteristic （ROC） curve. Results Totally 65 patients accomplished the therapy, and 7 （10.8%） patients achieved HBsAg loss. HBsAg loss at week 48 of treatment was associated with HBeAg level at week 12 of treatment （Fisher＇s exact test, P = 0. 023）, HBeAg level at week 24 （Fisher＇s exact test, P=0. 004）, and lower HBsAg levels （〈250 IU/mL） at week 12 and 24 of treatment （Fisherrs exact test,P=0. 001 and 0. 002, respectively）. HBsAg loss was associated with HBV DNA negative （〈1000 copy/mL） at week 12 of treatment （Fisher＇s exact test,P=0. 039）, while not associated with HBV DNA negative at week 24 of treatment （Fisher＇s exact test, P=0. 130）. ROC curve analysis revealed that the AUC was 0. 8584（P=0. 0021） of HBsAg level at week 12, 0. 9606（P=0. 001） of HBsAg level at week 24, and 0. 8350（P=0. 040） of HBeAg level at week 24. Conclusion Levels of HBsAg and HBeAg at week 24 of treatment might serve as effective factors to predict HBsAg loss in patients received PEG-IFN monotherapy.